MEDICINA NUCLEARE - Crosetto Foundation

BIBLIOGRAFIA
1. Mukhtar, M. (2005) Evolution of biomarkers: drug discovery to personalized medicine. Drug Discov. Today 10, 1216–
1218
2. Ross, J.S. and Ginsburg, G.S. (2002) Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient
care. Drug Discov. Today 7, 859–864
3. Sadee, W. and Dai, Z. (2005) Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14 (Spec No. 2),
R207–R214
4. Nunn, A.D. (2007) Molecular imaging and personalized medicine: an uncertain future. Cancer Biother. Radiopharm. 22,
722–739
5. Myers, W.G. (1979) Georg Charles de Hevesy: the father of nuclear medicine. J. Nucl.Med. 20, 590–594
6. Hevesy, G. and Paneth, F. (1938) A Manual of Radioactivity (2nd edn), Oxford University Press
7. Ehrlich, C. (1908) Experimental Researches on Specific Therapy. On Immunity with Special Reference to the Relationship
between Distribution and Action of Antigens. Royal Institute of Public Health. Lewis p. 107
8. Witkop, B. (1999) Proc. Am. Philos. Soc. 143, 540–557
9. Sokoloff, L. et al. (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory,
procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897–916
10. Meikle, S.R. et al. (2006) Complementary molecular imaging technologies: high resolution SPECT, PET and MRI. Drug
Discov. Today: Technol. 3, 187-194
11. Miller, J.C. and Thrall, J.H. (2004) Clinical molecular imaging. J. Am. Coll. Radiol. 1 (Suppl.), 14–23
12. Therasse, P. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J.
Natl. Cancer Inst. (Bethesda) 92, 205–216
13. Eckelman, W.C. (1995) Radiolabeling with 99mTc to study high capacity and low capacity biochemical systems. Eur. J.
Nucl. Med. 22, 249–263
14. Weissleder, R. et al. (1990) MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
Am. J. Roentgenol. 155, 1161 1167
15. Vera, D.R. et al. (1995) A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver. Acad.
Radiol. 2, 497–506
16. Bolo, N.R. et al. (1987) Fluorodeoxyglucose brain metabolism studied by NMR and PET. Ann. N. Y. Acad. Sci. 508, 451–
459
17. Brix, G. et al. (1996) Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F
MRI: a comparative animal study. Nucl. Med. Biol. 23, 897–906
18. Weissleder, R. et al. (2000) In vivo magnetic resonance imaging of transgene expression. Nat. Med. 6, 351–355
19. Carrasquillo, J.A. (1989) Radioimmunoscintigraphy with polyclonal or monoclonal antibodies. In Antibodies in
Radiodiagnosis and Radiotherapy (Zalutsky, M.R., ed.), pp.169–198, CRC Press
20. (Eckelman, W.C., ed.), Receptor Binding RadiotracersCRC Press
21. Eckelman, W.C. et al. (1979) Receptor binding radiotracers: a class of potential radiopharmaceuticals. J. Nucl. Med. 20,
350–357
22. Kung, M.P. and Kung, H.F. (2005) Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl. Med.
Biol. 32, 673–678
23. Selikson Gibson, R.E. et al. (1980) Calculation of binding isotherms when ligand and receptor are in different volumes of
distribution. Anal. Biochem. 108, 64–71
24. Christian, B.T. et al. (2004) Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET
multiple-injection protocol. J. Cereb. Blood Flow Metab. 24, 309–322
25. Zambrowicz, B.P. and Sands, A.T. (2003) Knockouts model the 100 best-selling drugs – will they model the next 100?
Nat. Rev. Drug Discov. 2, 38–51
26. Eckelman, W.C. (2006) Finding the right targeted probe for the right target for the right disease. In Proceedings of the
Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine (Mazzi, U., ed.), In Servizi Grafici
Editoriali snc, Padova, Italy. pp. 657–664
27. Shimoji, K. et al. (2003) Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP
in vivo is not due to agonist-induced reduction in cerebral blood flow. Synapse 50, 151–163
28. Eckelman, W.C. (2003) The use of gene-manipulated mice in the validation of receptor binding radiotracer. Nucl. Med.
Biol. 30, 851–860
29. Laruelle, M. et al. (2002) Positron emission tomography: imaging and quantification of neurotransporter availability.
Methods 27, 287–299
AIMN - Notiziario elettronico di Medicina Nucleare ed Imaging Molecolare, Anno V, n 2, 2009 pag. 23/85